Relationship between treatment of heart failure and B-Type natriuretic peptide

• Autor(a) principal: Barbosa,Grace Silva
• Data de Publicação: 2014
• Outros Autores: Pereira,Fernanda Veloso, Lima,Eloange Alkmim, Morais,Gabriel Bispo De, Barral,Ana Beatris Cézar Rodrigues, Sales,Galeno Hassen
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Geriatrics, Gerontology and Aging (Online)
• Texto Completo: https://ggaging.com/details/94
• topic: Heart failure; Therapeutics; Natriuretic peptides.

<p><b>INTRODUCTION:</b> The B-type natriuretic peptide (BNP) is a marker of heart failure (HF), which represents a serious public health problem. This marker is useful in the diagnosis, in estimating the prognosis and therapeutic guidance of HF.<br> <b>OBJECTIVE:</b> To review the scientific publications that establish the relationship between the pharmacological treatment of HF and the BNP.<br> <b>METHODOLOGY:</b> This is a bibliographical research of scientific articles published in the period from 2009 to 2013, available in Portuguese and English.<br> <b>RESULTS:</b> 100 articles were analyzed, 15 of which, with pertinent thematic, were used in this review.<br> <b>CONCLUSION:</b> The conduct intended to reduce plasma concentrations of BNP for concentrations within ranges of reference reduces cardiovascular events. When comparing the use of Losartan associated with hydrochlorothiazide with Anlodipina in high doses have similar efficacy in reducing levels of BNP, the beta blockers cause fall in weeks to months, being the most effective.</p>